Glucagon-like peptide-1 inhalation - MannKind Corporation

Drug Profile

Glucagon-like peptide-1 inhalation - MannKind Corporation

Alternative Names: GLP-1/Technosphere®; MKC 253; MKC253 Inhalation Powder

Latest Information Update: 21 Apr 2011

Price : $50

At a glance

  • Originator MannKind Corporation
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 28 Feb 2011 Discontinued - Phase-I for Type-2 diabetes mellitus in Netherlands (Inhalation)
  • 02 Oct 2009 Efficacy data from a phase I trial in Type-2 diabetes mellitus, comparing the effects of MKC 253 with exenatide presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD-2009)
  • 09 Jun 2009 Pharmacodynamics and pharmacokinetics data from phase I trials in Healthy volunteers and Type-2 diabetes mellitus presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009) ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top